Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.54 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19691022 | 0.93 | ADORA2A (0.55) | ADORA2APOLBADORA1KCNN3MAPT | |
| SCHEMBL19690885 | 0.87 | POLB (0.62) | ADORA2APOLBADORA1KCNN3MAPT | |
| SCHEMBL19690822 | 0.86 | ADORA2A (0.54) | ADORA2APOLBADORA1KCNN3MAPT | |
| SCHEMBL19690954 | 0.86 | ADORA2A (0.56) | ADORA2APOLBADORA1KCNN3MAPT | |
| SCHEMBL19690984 | 0.85 | ADORA2A (0.55) | ADORA2APOLBADORA1KCNN3MAPT | |
| SCHEMBL19690860 | 0.85 | HTT (0.43) | ADORA2APOLBADORA1KCNN3MAPT | |
| SCHEMBL19690943 | 0.84 | ADORA2A (0.59) | ADORA2APOLBADORA1MAPTALOX15 | |
| SCHEMBL19690896 | 0.79 | ADORA2A (0.55) | ADORA2APOLBADORA1MAPTALOX15 | |
| SCHEMBL25192892 | 0.79 | POLB (0.83) | POLBKCNN3ALOX15 | |
| SCHEMBL19690934 | 0.78 | ADORA2A (0.56) | ADORA2APOLBADORA1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1792/4885POLB 4779/4885ADORA1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.